209 related articles for article (PubMed ID: 12372943)
1. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
Matsuhashi N; Yoshioka T
Nephron; 2002; 92(3):601-4. PubMed ID: 12372943
[TBL] [Abstract][Full Text] [Related]
2. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW
J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037
[TBL] [Abstract][Full Text] [Related]
3. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.
Sitter T; Bergner A; Schiffl H
Nephrol Dial Transplant; 2000 Aug; 15(8):1207-11. PubMed ID: 10910446
[TBL] [Abstract][Full Text] [Related]
4. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
Gaughan WJ; Liss KA; Dunn SR; Mangold AM; Buhsmer JP; Michael B; Burke JF
Am J Kidney Dis; 1997 Oct; 30(4):495-500. PubMed ID: 9328363
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
6. Anemia and carnitine supplementation in hemodialyzed patients.
Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
[TBL] [Abstract][Full Text] [Related]
7. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
8. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
DeVita MV; Frumkin D; Mittal S; Kamran A; Fishbane S; Michelis MF
Clin Nephrol; 2003 Nov; 60(5):335-40. PubMed ID: 14640239
[TBL] [Abstract][Full Text] [Related]
9. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
Cotter DJ; Thamer M; Kimmel PL; Sadler JH
Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
[TBL] [Abstract][Full Text] [Related]
11. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
Walter J; Gål J; Taraba I
Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin treatment of anemia in renal transplant patients.
Lezaic V; Djukanovic L; Pavlovic-Kentera V
Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243
[TBL] [Abstract][Full Text] [Related]
13. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
Carlini R; Obialo CI; Rothstein M
Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
[TBL] [Abstract][Full Text] [Related]
14. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid.
Bonforte G; Grillo P; Zerbi S; Surian M
Blood Purif; 2002; 20(4):357-63. PubMed ID: 12169845
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
16. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
[TBL] [Abstract][Full Text] [Related]
17. Study of association between interleukin-17 and interferon-gamma and recombinant human erythropoietin dose in patients undergoing peritoneal dialysis.
de Oliveira WV; de Figueiredo RC; de Paula AS; Turani SD; Velloso MSS; Pinheiro MB; Gomes KB; Marinho MAS; Pinto SWL; Rios DRA
Cytokine; 2017 Aug; 96():24-29. PubMed ID: 28282547
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
19. Effect of hyperparathyroidism on response to erythropoietin in children on dialysis.
Belsha CW; Berry PL
Pediatr Nephrol; 1998 May; 12(4):298-303. PubMed ID: 9655362
[TBL] [Abstract][Full Text] [Related]
20. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
